|
|
|
| Efficacy and safety of Olanzapine compared with Risperidone in the treatment of mental and behavioral symptoms of Alzheimer’s disease：a meta-analysis |
| HAN Fuhua1,2 OUYANG Jiahui1 TAO Zhuang3 ZHAN Min2 QIAO Dandan2 CHEN Wenjie2 SUN Linjuan2 JIAO Xiuzhen4 |
1.Graduate School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Encephalopathy, Xiyuan Hospital, Chinese Academy of Chinese Medical Sciences, Beijing 100091, China;
3.Basic Research Office, Institute of Basic Theory of Traditional Chinese Medicine, Chinese Academy of Chinese Medical Sciences, Beijing 100700, China; 4.Department of Encephalopathy, Botou Hospital of Traditional Chinese Medicine, Hebei Province, Cangzhou 061000, China |
|
|
|
Abstract Objective To systematically evaluate the efficacy and safety of Olanzapine compared with Risperidone in the treatment of mental and behavioral symptoms of Alzheimer’s disease, in order to provide evidence-based reference for rational clinical drug use. Methods PubMed, Embase, Cochrane Library, CNKI, Wanfang Database, VIP Database and Chinese Biomedical Literature Database were searched by computer. Randomized controlled trials (RCT) of Olanzapine (experimental group) compared with Risperidone (control group) in the treatment of mental and behavioral symptoms of Alzheimer’s disease from inception to published in August 2020 of each database were collected. Literature was screened, data were extracted, literature quality was evaluated using the Cochrane handbook for systematic reviews of bias risk assessment tool, and meta-analysis was performed using Rev Man 5.3 software. Results A total of 13 studies were included, with a total of 1448 patients. Meta-analysis showed that the total effective rate of experimental group (RR = 1.14, 95%CI [1.06, 1.23], P = 0.0008) was significantly higher than that of control group. After two weeks of treatment (WMD = -2.67, 95%CI [-3.79,-1.55], P < 0.000 01) and four weeks later (WMD = -2.83, 95%CI [-4.02,-1.65], P < 0.000 01) the scores of rating scale of the behavioral pathology in Alzheimer’s disease in experimental group were significantly lower than those in control group. After eight weeks of treatment, there were no significant differences between the two groups in the scores of rating scale of the behavioral pathology in Alzheimer’s disease (WMD = -1.40, 95%CI [-4.34, 1.54], P = 0.35) and the scores of mini mental state examination (WMD = 1.01, 95%CI [-1.73, 3.76], P = 0.47). The incidence of extrapyramidal reaction in experimental group (RR = 0.52, 95%CI [0.34, 0.80], P = 0.003) and the incidence of insomnia in experimental group (RR = 0.49, 95%CI [0.32, 0.76], P = 0.002) were significantly lower than those in control group. There were no significant differences in the incidence of headache, fatigue, blurred vision, irritation, liver function, increased body mass and lethargy between the two groups (P ＞ 0.05). Conclusion Olanzapine is more effective than Risperidone in the treatment of mental and behavioral symptoms of Alzheimer’s disease, and the incidence of extrapyramidal reaction and insomnia is lower than Risperidone.
|
|
|
|
|
|
[1] 陈晓春，张杰文，贾建平，等.2018中国痴呆与认知障碍诊治指南（一）：痴呆及其分类诊断标准[J].中华医学杂志.，2018（13）：965-970.
[2] Youn JC，Dong YL，Jin HJ，et al. Prevalence of neuropsychiatric syndromes in Alzheimer’s disease（AD）[J]. Arch Gerontol Geriatr，2011，52（3）：258-263.
[3] 徐攀.老年痴呆精神行为症状的药物治疗（综述）[J].中国城乡企业卫生，2010（2）：15-17.
[4] 孙达亮，王立娜.非典型抗精神病药治疗痴呆伴发的精神行为症状的研究进展[J].中华老年医学杂志，2018，37（2）：240-244.
[5] 热衣汗尼沙·祖农.奥氮平与利培酮治疗老年痴呆精神行为症状的疗效比较研究[J].临床合理用药杂志，2019， 12（3）：68-69.
[6] 蒋文竹，沙江明，刘澄英.奥氮平及利培酮治疗老年痴呆精神行为症状的疗效及安全性研究[J].实用老年医学，2015，29（8）：679-681.
[7] 石宇，田方圆，李海霞，等.利培酮对比氟哌啶醇治疗老年痴呆精神行为症状有效性和安全性的Meta分析[J].中国药房，2019，30（24）：3437-3442.
[8] 李欢欢，程仙送，蒋锋，等.奥氮平与利培酮治疗老年痴呆精神行为障碍的临床疗效[J].临床医学研究与实践，2018，3（32）：10-11.
[9] Deberdt WG，Dysken MW，Rappaport SA，et al. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia [J]. Am J Geriatr Psychiatry，2005，13（8）：722-730.
[10] 中华医学会精神科分会.中国精神障碍分类与诊断标准第3版[M].济南：山东科学技术出版社，2001：9-168.
[11] Lynna Lan Tien Nguyen Do. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders（DSM-Ⅳ）[J]. Springer US, 2011.
[12] Vladimir Hachinski，Costantino Iadecola，Ron C Petersen，et al. 美国国立神经疾病和卒中研究所-加拿大卒中网血管性认知障碍统一标准[J].国际脑血管病杂志，2007， 15（1）：4-24.
[13] De Deyn PP, Wirshing WC. Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia[J]. J Clin Psychiatry，2001，62（21）：19-22.
[14] 于荣焕，王荫华.画钟试验和MMSE对阿尔茨海默病筛查的临床意义[J].中国康复理论与实践，2004，10（3）：2.
[15] 盛建华，陈美娟.阿尔茨海默病病理行为评分表信度和效度[J].临床精神医学杂志，2001，11：57-59.
[16] 喻东山，高振忠.精神科合理用药手册[M].南京：江苏科学技术出版社，2005：162-163.
[17] Higgins JPT，Green S. Collaboration TC. Cochrane handbook for systematic reviews of interventions [EB/OL]. [2015-12-10]. http：//www.cochrane handbook.org.
[18] 马灵芝，苏燕玲，胡艳芳，等.为老年痴呆症患者使用奥氮平进行治疗在改善其精神障碍及行为障碍方面的效果[J].当代医药论丛，2020，18（9）：155-156.
[19] 蒋爱平.奥氮平与利培酮治疗老年期痴呆神经精神症状的疗效对比分析[J].世界临床医学，2017，11（9）：5-6.
[20] 田怡，王家祺.奥氮平与利培酮治疗老年痴呆精神行为症状的疗效对比探究[J].海峡药学，2016，28（4）：188-189.
[21] 罗海龙.奥氮平与利培酮治疗老年痴呆精神行为症状的疗效比较[J].河北医学，2013，19（11）：1633-1636.
[22] 钟华，刘少华.奥氮平与利培酮治疗阿尔茨海默病患者伴精神行为症状的效果比较[J].中国当代医药，2015， 22（35）：145-147.
[23] 李立杰.奥氮平对老年痴呆伴发精神行为障碍患者的治疗研究[J].吉林医学，2014，35（19）：4207-4208.
[24] 魏娟，谢江涛，武兴兴，等.奥氮平治疗对改善老年痴呆精神行为障碍的临床疗效分析[J].国际精神病学杂志，2015，42（6）：41-44.
[25] 王平生.奥氮平治疗老年痴呆伴精神障碍的临床疗效[J].临床合理用药杂志，2017，10（33）：61-62.
[26] 熊飞东.奥氮平治疗老年痴呆精神行为障碍的临床效果观察[J].河南医学研究，2017，26（11）：2036-2037.
[27] 何金珠.奥氮平治疗老年痴呆伴精神行为障碍分析[J].中国卫生标准管理，2020，11（3）：75-77.
[28] Conde-Sala JL，Turró-Garriga O，Pi?觡án-Hernández S，et al. Effects of anosognosia and neuropsychiatric symptoms on the quality of life of patients with Alzheimer’s disease：a 24-month follow-up study [J]. Int J Geriatr Psychiatry，2016，31（2）：109-119.
[29] 刘彩霞，许瑛，严静，等.养老机构老年痴呆患者行为精神症状与照料者负担的相关性[J].中华老年医学杂志，2017，36（5）：522-527.
[30] 中国老年医学学会认知障碍分会，认知障碍患者照料及管理专家共识撰写组.阿尔茨海默病患者日常生活能力和精神行为症状及认知功能全面管理中国专家共识（2019）[J].中华老年医学杂志，2020，39（1）：1-2.
[31] 孙达亮，王立娜.非典型抗精神病药治疗痴呆伴发的精神行为症状的研究进展[J].中华老年医学杂志，2018， 37（2）：240-244.
[32] Nagai N，Watanabe K. Olanzapine [J]. Nihon Rinsho，2013， 71（4）：666-672.
[33] 王在亮.奥氮平与利培酮治疗老年性痴呆精神行为症状的临床对比分析[J].中国实用医药，2019，14（1）：97-98.
[34] 梁月兰.奥氮平治疗老年痴呆伴发精神行为障碍临床观察[J].实用临床医药杂志，2015，19（19）：88.
[35] 卢浩扬，江晓佳，尚德为，等.利培酮在精神分裂症患者中的血清药物浓度/剂量比影响因素研究[J].中国临床药理学杂志，2018，34（2）：117-119. |
|
|
|
